The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary.
Clinical Trials Registration. NCT01782300.
Keywords: dengue vaccine; live attenuated tetravalent; clinical trial
Journal Article. 2803 words.
Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology
Full text: subscription required